Literature DB >> 10385267

Nitrergic and purinergic mechanisms and their interactions for relaxation of the rat internal anal sphincter.

A De Luca1, C G Li, M J Rand.   

Abstract

1. The NANC neuronal mechanisms for relaxations of the rat internal anal sphincter in response to electrical field stimulation (EFS) were studied in isolated preparations in the presence of atropine (1 microM), propranolol (3 microM) and phentolamine (3 microM). 2. EFS-induced relaxations were abolished by tetrodotoxin (1 microM) and reduced to 64% of control by the guanylate cyclase inhibitor ODQ (1 microM), but were not significantly reduced by the nitric oxide synthase inhibitor L-NAME (100 microM) or oxyhaemoglobin (10 microM). However, in the presence of tubocurarine (10 microM) or apamin (0.1 microM), L-NAME or oxyhaemoglobin greatly reduced or abolished EFS-induced relaxations. 3. The EFS-induced relaxations were mimicked by NO (10-100 microM) and by ATP (3-10 mM). The relaxations elicited by these agents were not affected by tetrodotoxin, L-NAME, tubocurarine or apamin. However, ATP-induced relaxations were reduced by the combination of L-NAME with tubocurarine or apamin. 4. Nicotine (10-100 microM) produced concentration-dependent relaxations that were abolished by tubocurarine (10 microM) or hexamethonium (200 microM). After desensitisation to nicotine (100 microM) and in its continued presence, the addition of L-NAME (100 microM) resulted in almost complete abolition of EFS-induced relaxations. 5. It is suggested that tubocurarine, hexamethonium and desensitisation to nicotine have an apamin-like action in the rat internal anal sphincter, the main effect being blockade of a purinergic component of the relaxant transmission process. 6. The findings suggest that both nitrergic and purinergic transmissions are involved in EFS-induced NANC relaxations of the rat internal anal sphincter, and there appears to be a complex interaction between these two pathways of transmission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385267     DOI: 10.1046/j.1365-2680.1999.00114.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  7 in total

1.  Comparison of inhibitory neuromuscular transmission in the Cynomolgus monkey IAS and rectum: special emphasis on differences in purinergic transmission.

Authors:  C A Cobine; M McKechnie; R J Brookfield; K I Hannigan; K D Keef
Journal:  J Physiol       Date:  2018-10-13       Impact factor: 5.182

2.  Interstitial cells of Cajal are involved in the afferent limb of the rectoanal inhibitory reflex.

Authors:  F de Lorijn; W J de Jonge; T Wedel; J M Vanderwinden; M A Benninga; G E Boeckxstaens
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

3.  Evidence that ATP or a related purine is an excitatory neurotransmitter in the longitudinal muscle of mouse distal colon.

Authors:  M G Zizzo; F Mulè; R Serio
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

4.  Inhibitory responses to exogenous adenosine in murine proximal and distal colon.

Authors:  Maria Grazia Zizzo; Flavia Mulè; Rosa Serio
Journal:  Br J Pharmacol       Date:  2006-07-03       Impact factor: 8.739

5.  Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.

Authors:  Jagmohan Singh; Vaibhav Mehendiratta; Francesco Del Galdo; Sergio A Jimenez; Sidney Cohen; Anthony J DiMarino; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-24       Impact factor: 4.052

6.  Functional role of vasoactive intestinal polypeptide in inhibitory motor innervation in the mouse internal anal sphincter.

Authors:  K D Keef; S N Saxton; R A McDowall; R E Kaminski; A M Duffy; C A Cobine
Journal:  J Physiol       Date:  2013-01-21       Impact factor: 5.182

Review 7.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.